https://www.selleckchem.com/products/azd7648.html
to curative-intent RT.The chemokine receptor CXCR4, which is overexpressed in many solid and hematologic malignancies, can be targeted for radiopeptide therapy via the antagonist Pentixather®. Biokinetics and dosimetry of 177Lu-Pentixather and 90Y-Pentixather were analyzed. Methods This retrospective study is a standardized reevaluation of data collected for treatment planning. Nineteen patients with complete sets of planar whole-body scans over at least four days and a single SPECT/CT after 200 MBq 177Lu-Pentixather were included. Kine